Clinical trials
Prostate cancer clinical trials
Cancer of the prostate gland, one of the most common cancers in men. We’re tracking 1,219 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07042243Recruiting
Florida ASCENT cancer study for patients and providers
This study looks at cancer care in Florida. If you have had cancer in the past and are not currently getting active treatment (like chemotherapy or radiation), this study may help researchers understand how to improve care.
Gainesville, FloridaAges 18–100 - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Los Angeles, CaliforniaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT06678828Enrolling by invitation
Testing a new blood test for prostate cancer risk
This study is testing a new blood test, ClarityDX Prostate, to see if it can help doctors better decide who needs a biopsy. It is for men who have been referred to a urologist because there is a suspicion of prostate cancer but who have not been diagnosed yet.
Calgary, AlbertaAges 18 years+ - NCT06168487RecruitingPhase 1
Telmisartan for stable prostate cancer
This trial tests the blood pressure medication telmisartan in men with prostate cancer who are already on a stable treatment and not needing an immediate change. The goal is to see if adding telmisartan can help control the cancer without extra side effects.
Lebanon, New HampshireAges 18 years+ - NCT05438563Recruiting
MRI-guided prostate cancer ablation with ultrasound from the urethra
This trial tests a newer way to treat certain low- to intermediate-risk prostate cancers using MRI guidance and an ultrasound probe placed through the urethra. It aims to destroy the tumor while using imaging to help target it more precisely.
Rochester, MinnesotaAges 45–80 - NCT06096870RecruitingPhase 2
Enzalutamide with a new drug for prostate cancer that is active on PET scan
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
Bethesda, MarylandAges 18–120 - NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
Brooklyn, New YorkAges 18 years+ - NCT06111781RecruitingPhase 2
Hormone Therapy and Radiation for Intermediate Risk Prostate Cancer
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
New Haven, ConnecticutAges 18 years+ - NCT06378866RecruitingPhase 2
Radiation with hormone therapy timing for prostate cancer
This study is testing whether using focused radiation beams (SBRT) right away or later, along with hormone therapy, can help control prostate cancer that has returned in a few spots outside the pelvis. The goal is to find the best timing for combining radiation and hormone treatment.
Phoenix, ArizonaAges 18 years+ - NCT07710807Recruiting
Comparing two prostate biopsy methods
This trial compares two ways to take a prostate biopsy (through the rectum or through the skin between the scrotum and anus) to see which is more accurate. Men with suspicious MRI findings (PI-RADS 3, 4, or 5) who haven't had prostate cancer before may be eligible.
Ankara, YenimahalleAges 50–75 - NCT06067269RecruitingPhase 2
Hormone therapy and precise radiation for intermediate-risk prostate cancer
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
Los Angeles, CaliforniaAges 18 years+ - NCT07365423RecruitingPhase 2
Terbinafine for prostate cancer with rising PSA
This trial tests if the antifungal drug terbinafine can lower PSA levels in men whose prostate cancer has returned after standard treatments, but who are not yet ready for hormone therapy. It is for men with no distant spread seen on scans except possibly small lymph nodes.
BadenAges 18 years+ - NCT05958082Recruiting
Genetic testing education for Black men with prostate cancer
This study tests whether educational support helps Black men with high-risk prostate cancer complete genetic testing. It may make it easier to get genetic results that can guide care for you and your family.
Detroit, MichiganAges 18 years+ - NCT03079323RecruitingPhase 2
Radiation before or after surgery for prostate cancer spread to lymph nodes
This Phase 2 trial studies whether giving planned radiation to certain lymph node areas (para-aortic/“PART”) after surgery helps people whose prostate cancer has spread to lymph nodes (pN1). You would be screened after a specific lymph node surgery (ePLND) to see if you match their situation, then receive the trial’s radiation plan and follow-up.
LeuvenAges 18 years+ - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Birmingham, AlabamaAges 21 years+ - NCT03294889RecruitingPhase 1/Phase 2
Single-dose SBRT for early prostate cancer
This trial tests a very short, one-time form of radiation (SBRT) to treat prostate cancer. It aims to see whether treating the prostate in one shot is safe and effective for carefully selected patients.
GenevaAges 18–85 - NCT03327675Recruiting
PET imaging test to plan personalized prostate cancer treatment
This trial tests a high-precision scan that uses a prostate cancer marker to show where cancer may be. The goal is to use the scan results to better plan treatment, especially around surgery and lymph nodes, in certain patients with prostate cancer.
LeuvenAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT03474913Recruiting
Upright MRI to help screen for prostate cancer
This study checks whether an MRI done while you are in an upright position can help with prostate cancer screening. If you have been advised to get a prostate MRI, the researchers may also do an ultrasound-guided biopsy to confirm results.
New York, New YorkAges 18–100 - NCT03492424Recruiting
Focal prostate cancer treatment study
This study looks at outcomes after “focal therapy,” a type of treatment that targets only part of the prostate, for people with newly diagnosed or returning prostate cancer. It may help researchers understand how well this targeted approach works and for whom.
New York, New YorkAges 18 years+ - NCT03495427RecruitingPhase 2/Phase 3
PSMA PET scan to find early prostate cancer spread
This study uses a PSMA PET scan to look for early spread of prostate cancer in men with higher-risk genetic test results (Decipher score above 0.45). It may help doctors spot metastases sooner so treatment decisions can be better targeted.
Tampa, FloridaAges 18 years+ - NCT03594760RecruitingPhase 3
PSMA PET scan study using advanced computer imaging in prostate cancer
This Phase 3 study looks at how a PSMA PET scan can predict how prostate cancer will progress and how well treatment is working. If your doctor at CHUM orders this scan, you may be able to join to help refine better predictions for future patients.
Montreal, QuebecAges 18 years+ - NCT03650595Recruiting
MRI-guided laser treatment for prostate cancer
This trial tests a minimally invasive prostate treatment using MRI guidance and a focal laser to destroy only the cancer spot (not the whole prostate). If you have low-to-intermediate risk, MRI-visible prostate cancer in a limited area, it may help control the cancer while potentially reducing treatment side effects.
Toronto, OntarioAges 40–80
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer?
- Yes. Clin2 currently lists 1,219 recruiting prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.